Developments Amplia reports more responses and improved OS in pancreatic cancer trial Amplia Therapeutics (ASX: ATX; OTCQB: INNMF) has announced data from the ongoing ACCENT clinical trial of narmafotinib combined with chemotherapy in advanced pancreatic cancer showing a median overall survival (OS) of... March 23, 2026